ClinicalTrials.gg
RecruitingNCT07596966Updated May 19, 2026

EFFECTS OF PROPOLIS AND ROYAL JELLY SUPPLEMENTATION ON INFLAMMATORY AND OXIDATIVE STRESS MARKERS IN PATIENTS WITH SYSTEMIC ARTERIAL HYPERTENSION

An interventional study of Placebo and Royal Jelly + Propolis Group in Systemic Arterial Hypertension and Inflammation, sponsored by Universidade Federal Fluminense. Recruiting at 1 site in Brazil. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-05-19.

Sponsored by Universidade Federal Fluminense · Not applicable, Interventional, and Health services research

How we know

From the registry’s dates

  • Registered 6 months after the study started (first participant enrolled Oct 2025, registered May 2026).
  • Started Oct 2025; still recruiting 1 year 1 month later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
48
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 209 studies in Hypertension with a site in Brazil — 28 open to participants now, 33 under way, 6 of them phase 3. Hypertension · Brazil.

Planned enrollment
128th of 189
48 · median 80
Started
2025
with 11 others
No phase
112 of 209
15 open now
Primary completion
2026-12
later than 10 of 32 live
Registered
206th of 209
by date

Among the 209 studies in Hypertension with a site in Brazil, this one is the 128th largest by planned enrollment of the 189 interventional ones that give a count, is one of 12 that started in 2025, is one of 112 with no phase, reaches primary completion later than 10 of the 32 other live ones, and was the 206th registered.

Hypertension

6,128 studies on the registry are indexed under Hypertension; 907 are open to participants now.

Browse Hypertension studies →

Open to participants now

28 of the 209 studies in Hypertension with a site in Brazil are open now. Recruiting first, the newest first:

22 more — sign in →

All 28 open studies →

A study can be open while its sites in Brazil have not opened yet or have stopped. Only those recruiting at a site in Brazil →

Who these studies take

Of the 552 Hypertension studies recruiting now, 260 (47%) set no upper age limit and 198 (36%) stop at 75 or younger; 40 take children under 18; 136 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 209 studies in Hypertension with a site in Brazil, or all of them as a file.
02

Study summary

The study aims to evaluate the effect of the royal jelly and propolis on inflammation and oxidative stress in participants with systemic arterial hypertension. A longitudinal double-blind randomized clinical trial will be carried out, involving hypertensive participants for two months.

Read the detailed description

Royal jelly (RG) and propolis (P) are considered superfood that has been used in traditional medicine and dietary supplementation due to its antioxidant, anti-inflammatory, immunomodulatory, and regenerative properties. The antioxidant and anti-inflammatory effects of GR and P highlight their potential as a natural supplement for the prevention and management of several health conditions. Although in vitro and animal model data are promising, clinical studies are still needed to validate the effects of royal jelly and propolis in human populations.

03

Conditions studied

  • Systemic Arterial Hypertension
  • Inflammation

Keywords

  • inflammation
  • royal jelly
  • propolis
  • hypertension
  • oxidative stress
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosis of stage 1 and 2 hypertension
  • Regular treatment for more than 6 months
  • There have been no changes in medication doses over the last three months.

Exclusion criteria

Exclusion Criteria:

  • and infectious diseases, diabetes
  • Chronic kidney disease, liver disease, cancer and AIDS
  • Pregnant women
  • Use of catabolic drugs or antibiotics
  • Use of antioxidant vitamin supplements, prebiotics, probiotics, symbiotic
  • Habitual intake of royal jelly and propolis
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

05

Study design

Phase
Not applicable
Primary purpose
Health services research
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
48 participants (estimated)

Study arms

  • Experimental
    Royal Jelly + Propolis Group

    Participants will receive 4 capsules per day, providing the dosage of 300mg of royal jelly + 500mg propolis for 2 months (8 weeks).

    Dietary Supplement: Royal Jelly + Propolis Group

  • Placebo comparator
    Placebo Group

    The placebo group will receive 4 capsules per day (containing microcrystalline cellulose and magnesium stearate in colored gelatin capsules capable of masking the appearance of the internal content), at the same time for 2 months.

    Dietary Supplement: Placebo

Interventions

  • Dietary supplementPlacebo

    The placebo group will receive 4 capsules per day (containing microcrystalline cellulose and magnesium stearate in colored gelatin capsules capable of masking the appearance of the internal content), at the same time for 2 months.

  • Dietary supplementRoyal Jelly + Propolis Group

    Drug pages: Royal JellyStudies of Royal JellyRoyal Jelly pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record. · PropolisStudies of PropolisPropolis pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Participants will receive 4 capsules per day, providing the dosage of 300mg of royal jelly + 500mg propolis for 2 months (8 weeks).

06

What researchers measure

Primary outcomes

  1. Change of inflammatory citokynes

    Get blood samples to evaluate the supplementation effects in inflammatory cytokines such as interleukin 6 (IL-6, pg/mL), IL-1b (pg/mL), IL-17 (pg/mL) e TNF-α (pg/mL)

    Time frame: Baseline and 2 months

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No — Participant data will not be public to other research unless necessary.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2025 (actual). Primary completion is estimated for Dec 2026, 13 months after the start.

Of 1,407 non-industry interventional studies with no phase under Hypertension, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 41. This study's planned 13 months is below that.

Counting every sponsor, half of 1,502 studies reached it within 23 months; a quarter within 10 and three quarters within 42.

How these figures are worked out, and which studies are left out of them.

Registered
May 12, 2026
First posted
May 19, 2026
StartActual
Oct 15, 2025
Primary completionEst.
Dec 10, 2026
CompletionEst.
Dec 10, 2027
Last update
May 19, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 19, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07596966
Lead sponsor
Universidade Federal Fluminense
Responsible party
Sponsor
First posted
May 19, 2026
Start date
Oct 15, 2025
Primary completion
Dec 10, 2026 (estimated)
Completion
Dec 10, 2027 (estimated)
Last update
May 19, 2026

Study contacts

Denise Mafra, PhD
Contact
dmafra30@gmail.com
+5521985683003
Ludmila Cardozo, PhD
study director · Universidade Federal Fluminense

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Royal Jelly · Propolis

Start the discussion